Healthcare entity
All 1 tracked stories fall under one category: market-trends. Amgen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 132 original sources on average. We currently track 1 Healthcare story that mention Lipfendra (enlicitide), all published on July 16, 2026.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Amgen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 132 original sources on average. We currently track 1 Healthcare story that mention Lipfendra (enlicitide), all published on July 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lipfendra (enlicitide). Shared-story counts are live from our verified record — not editorial picks.
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Lipfendra (enlicitide) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
